<DOC>
	<DOCNO>NCT01246778</DOCNO>
	<brief_summary>Rationale : Recently , sunitinib ( tyrosine kinase inhibitor use treatment metastatic renal carcinoma gastrointestinal stroma tumor ) associate development heart failure , possibly off-target inhibition AMP-protein kinase . The investigator hypothesize sunitinib reduces contractile ability myocardium tolerance ischemia-reperfusion activator AMP-protein kinase atorvastatin AICAR reverse unwanted effect sunitinib . Objectives : The primary objective study investigate effect sunitinib ex-vivo atrial contractile force absence presence ischemia-reperfusion . A secondary objective explore atorvastatin AICAR prevent sunitinib-induced deterioration contractile function human atrial trabecula . Study design : Lab</brief_summary>
	<brief_title>Sunitinib Atrial Trabeculae Contractility</brief_title>
	<detailed_description>Study population : 44 ( +22 ) patient undergo CABG cardiac surgery extracorporal circulation Intervention ( applicable ) : none ( pharmacological intervention perform ex-vivo isolated atrial tissue ) Main study parameters/endpoints The developed force ex vivo atrial trabecula standardize stimulation .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Cardiac surgery extracorporal circulation Use oral antiarrhythmic theophylline use Use sulfonylureas Atrial arrythmias Right ventricular failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>